797 related articles for article (PubMed ID: 22468913)
1. The impact of assay technology as applied to safety assessment in reducing compound attrition in drug discovery.
Thomas CE; Will Y
Expert Opin Drug Discov; 2012 Feb; 7(2):109-22. PubMed ID: 22468913
[TBL] [Abstract][Full Text] [Related]
2. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
[TBL] [Abstract][Full Text] [Related]
3. Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience.
Vanderwall DE; Yuen N; Al-Ansari M; Bailey J; Fram D; Green DV; Pickett S; Vitulli G; Luengo JI; Almenoff JS
Drug Discov Today; 2011 Aug; 16(15-16):646-53. PubMed ID: 21601652
[TBL] [Abstract][Full Text] [Related]
4. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
[TBL] [Abstract][Full Text] [Related]
5. Molecular topology as a novel approach for drug discovery.
Gálvez J; Gálvez-Llompart M; García-Domenech R
Expert Opin Drug Discov; 2012 Feb; 7(2):133-53. PubMed ID: 22468915
[TBL] [Abstract][Full Text] [Related]
6. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
7. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
Meanwell NA
Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
[TBL] [Abstract][Full Text] [Related]
8. Towards quantitative biology: integration of biological information to elucidate disease pathways and to guide drug discovery.
Fischer HP
Biotechnol Annu Rev; 2005; 11():1-68. PubMed ID: 16216773
[TBL] [Abstract][Full Text] [Related]
9. Hit discovery and hit-to-lead approaches.
Keseru GM; Makara GM
Drug Discov Today; 2006 Aug; 11(15-16):741-8. PubMed ID: 16846802
[TBL] [Abstract][Full Text] [Related]
10. The value of in silico chemistry in the safety assessment of chemicals in the consumer goods and pharmaceutical industries.
Modi S; Hughes M; Garrow A; White A
Drug Discov Today; 2012 Feb; 17(3-4):135-42. PubMed ID: 22063083
[TBL] [Abstract][Full Text] [Related]
11. Alternative strategies in drug development: clinical pharmacological aspects.
Kuhlmann J
Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
[TBL] [Abstract][Full Text] [Related]
12. Case study: technology initiative led to advanced lead optimization screening processes at Bristol-Myers Squibb, 2004-2009.
Zhang L; Cvijic ME; Lippy J; Myslik J; Brenner SL; Binnie A; Houston JG
Drug Discov Today; 2012 Jul; 17(13-14):733-40. PubMed ID: 22425710
[TBL] [Abstract][Full Text] [Related]
13. Re-engineering drug discovery and development.
FitzGerald GA
LDI Issue Brief; 2011 Oct; 17(2):1-4. PubMed ID: 22049582
[TBL] [Abstract][Full Text] [Related]
14. Strategic applications of toxicogenomics in early drug discovery.
Ryan TP; Stevens JL; Thomas CE
Curr Opin Pharmacol; 2008 Oct; 8(5):654-60. PubMed ID: 18760379
[TBL] [Abstract][Full Text] [Related]
15. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
Kramer JA; Sagartz JE; Morris DL
Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
[TBL] [Abstract][Full Text] [Related]
16. Looking forward in pharmaceutical process chemistry.
Davies IW; Welch CJ
Science; 2009 Aug; 325(5941):701-4. PubMed ID: 19661417
[TBL] [Abstract][Full Text] [Related]
17. Portfolio management in early stage drug discovery - a traveler's guide through uncharted territory.
Betz UA
Drug Discov Today; 2011 Jul; 16(13-14):609-18. PubMed ID: 21600301
[TBL] [Abstract][Full Text] [Related]
18. [Strategy of molecular drug design: hits, leads and drug candidates].
Guo ZR
Yao Xue Xue Bao; 2008 Sep; 43(9):898-904. PubMed ID: 19048779
[TBL] [Abstract][Full Text] [Related]
19. Novel trends in high-throughput screening.
Mayr LM; Bojanic D
Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
[TBL] [Abstract][Full Text] [Related]
20. The future of drug discovery: enabling technologies for enhancing lead characterization and profiling therapeutic potential.
Janero DR
Expert Opin Drug Discov; 2014 Aug; 9(8):847-58. PubMed ID: 24965547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]